

## Revenues for the 1<sup>st</sup> half of 2011

- Further buoyant increase in activity
- First sales related to specific reimbursement in Germany (NUB)

**STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its revenues for the 1<sup>st</sup> half to 30 June 2011.**

- **2011 quarterly and half-year revenues\***

€ thousands* (unaudited)	Q1 2011	Q2 2011	Δ %	H1 2010	H1 2011	Δ %
<b>Revenues</b>	251.4	347.6	+38.3%	72.2	599.0	+729.6%

\* Revenues for the 1<sup>st</sup> and 2<sup>nd</sup> quarters of 2011 are unaudited.

Revenues totaled €347.6 thousand over the 2<sup>nd</sup> quarter of 2011, compared to €251.4 thousand the previous quarter, i.e. a sequential increase of +38.3%. Cumulative first-half revenues were eight times greater than the figure recorded over the first half of 2010, totaling €599.0 thousand over the first six months of 2011. The first half of 2011 thus saw an increase of +156.6% in activity compared to the second half of 2010.

- **Cash position**

On 30 June 2011, STENTYS had a net cash position of €18.5 million, in line with the Company's expectations and reflecting the strength of its balance sheet.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: *"We are very pleased with the growth of our activity, which is line with our expectations. It illustrates perfectly how well our self-apposing stents are being adopted in the context of the controlled release phase that is currently limited to certain key European hospitals. We have notably recorded our first sales in Germany related to the additional reimbursement granted at the start of the financial year."*

- **Next press release**

Financial results for the first half of 2011 will be published on 31 August 2011, after market.

### About STENTYS:

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

**More information on [www.stentys.com](http://www.stentys.com)**

### Stentys

Stanislas Piot  
CFO  
Tel.: +33 (0)1 44 53 99 42  
[stan.p@stentys.com](mailto:stan.p@stentys.com)

### NewCap.

Financial Communication / Investor & Press Relations  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[stentys@newcap.fr](mailto:stentys@newcap.fr)

STENTYS is listed on Compartment C of the NYSE Euronext Paris  
ISIN: FR0010949404 – Ticker: STNT